<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935984</url>
  </required_header>
  <id_info>
    <org_study_id>19-018</org_study_id>
    <nct_id>NCT03935984</nct_id>
  </id_info>
  <brief_title>Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity</brief_title>
  <official_title>Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProMedica Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toledo Health Science Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProMedica Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT
      exam within the past year will be included. Subjects will be treated with calcitonin to lower
      calcium levels immediately prior to reimaging. The goal of this study is to determine whether
      lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of
      SPECT-CT to localize parathyroid adenoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of SPECT-CT</measure>
    <time_frame>one year</time_frame>
    <description>conversion rate from non-localizing to localizing exam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical Approach</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of minimally-invasive surgery compared to four gland exploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Rate of patients in whom surgical intervention was successful in curing hyperparathyroidism</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Hypercalcemia</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin</intervention_name>
    <description>Treatment with calcitonin to lower high calcium levels prior to reimaging exam</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Miacalcin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary hyperparathyroidism

          -  Non-localizing SPECT-CT performed within 365 days prior to consent to participate in
             study

          -  Patient desires surgical intervention for treatment of PHPT

          -  No contraindications to 99mTC-Sestamibi

          -  No contraindications to treatment with calcitonin

          -  Serum calcium level prior to non-localizing SPECT-CT is â‰¥10.5 mg/dL

          -  Patient consents to participate and undergo second SPECT-CT for purposes of research

        Exclusion Criteria:

          -  Previous surgery to the neck, including resection of parathyroid tissue, except where
             end organ damage is present and further surgical intervention is medically necessary

          -  Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or
             adverse event during index SPECT-CT

          -  Allergy to calcitonin

          -  Hypocalcemia (contraindication to calcitonin)

          -  Vitamin D deficiency (contraindication to calcitonin)

          -  Previous treatment with radioactive iodine

          -  New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc.
             must be taken at time of index scan and research scan)

          -  Lithium exposure within one year of SPECT-CT (index and research scans)

          -  Secondary hyperparathyroidism

          -  Benign familial hypocalciuric hypercalcemia

          -  Known malignancy, particularly multiple endocrine neoplasia

          -  New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the
             time of index scan and second scan)

          -  Currently taking calcium channel blockers

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Jaume, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toledo College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Redfern, PhD</last_name>
    <phone>419-291-7517</phone>
    <email>roberta.redfern@promedica.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Seegert, MSN</last_name>
    <phone>419-291-7709</phone>
    <email>sara.seegert@promedica.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Redfern, PhD</last_name>
      <phone>419-291-7517</phone>
      <email>roberta.redfern@promedica.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ProMedica Health System</investigator_affiliation>
    <investigator_full_name>Juan Jaume</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

